Selected Realized Investments

Actelion is a biopharmaceutical company focusing on the discovery, development and commercialization of innovative treatments to serve high unmet medical needs. (SWX: ATLN)
Innovative vaccines. (Acquired by MedImmune.)
Cellective Therapeutics
Novel therapeutic antibodies for cancer and autoimmune diseases. (Acquired by MedImmune.)
Civitas Therapeutics
Civitas was a privately held biopharmaceutical company focused on developing and commercializing transformative therapeutics using its proprietary ARCUS™ technology, with an initial focus on treating OFF episodes in patients with Parkinson’s disease. The company was acquired by Acorda Therapeutics (NASDAQ:ACOR) in 2014.
Drugs for pulmonary diseases. (Acquired by Actelion.)
Durata Therapeutics
Durata was a biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases. Durata’s lead product candidate, Dalbavancin, was approved by the FDA in May of 2014. Durata was acquired by Actavis in October of 2014.
Small molecule oncology drugs targeting the PI3K/mTOR pathway. (Acquired by Takeda).
Products for antibiotic-resistant infectious diseases. (Nasdaq: ITMN)
Kosan Biosciences
Novel polyketides for development as potential therapeutics. (Nasdaq: KOSN)
Labrys Biologics
Development stage biotechnology company focused on treatments for chronic migraine (acquired by TEVA).
Millennium Pharmaceuticals
Therapeutic drug development. (Nasdaq: MLNM)
Movetis is a specialty GI company that is discovering, developing and commercialising treatments targeting GI conditions with a high unmet medical need. The company’s lead drug Resolor® (prucalopride) is approved in the European Economic Area for the indication “symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief”. Two more products are in Phase II development and Movetis has two prioritised compounds in preclinical development. (Acquired by Shire plc)
NextWave Pharmaceuticals
Therapeutics focused on pediatric ADHD. (Acquired by Pfizer).
Orexigen is a biopharmaceutical company focused on the treatment of obesity. The company’s lead combination product candidates targeted for obesity are Contrave® (naltrexone SR/bupropion SR), which has completed Phase 3 clinical trials and has submitted an NDA for FDA review, and Empatic™ (zonisamide SR/bupropion SR), which has completed Phase 2 clinical development. (Nasdaq: OREX)
PregLem is a specialty biopharmaceutical company dedicated to the development and commercialisation of innovative drugs for women’s reproductive medicine. (Acquired by Gideon Richter)
A biopharmaceutical company developing drugs for chronic disorders of the central nervous system, such as chorea associated with Huntington's disease. (Acquired by Biovale.)
Salveo Specialty Pharmacy
Salveo, was a private company headquartered in Saint Petersburg, FL, focused on creating a leading specialty pharmacy organization serving patients and customers across the country. The company was acquired by Catamaran (NASDAQ:CTRX) in 2015.
SARcode Bioscience
Therapeutics targeting dry eye disease. (Acquired by Shire)
Seattle Genetics
Antibodies to treat cancer. (Nasdaq: SGEN)
TESARO is a oncology-focused biopharmaceutical company focused on improving the lives of cancer patients by developing safer and more effective therapeutics and supportive care products. TESARO was co-founded by former executives of MGI Pharma, an oncology company that was acquired in 2008 for $3.9B. (NASDAQ:TSRO)
Threshold Pharmaceuticals
Targeted cancer therapy. (Nasdaq: THLD)
Trius Therapeutics
Antibiotics for gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). (Nasdaq: TSRX)
Vicept Therapeutics
Vicept is a biopharmaceutical company focused on the development of the first effective topically-applied treatment for the skin redness associated with rosacea, and pursuing additional indications that include the treatment and prevention of actinic (solar) purpura and peri-procedural bruising of the skin.